



biologics

an Open Access Journal by MDPI

Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes

Guest Editors:

Prof. Dr. Vasso Apostolopoulos

Institute for Health and Sport,
Victoria University, Melbourne,
VIC 3011, Australia

Dr. Vivek P. Chavda

Department of Pharmaceutics
and Pharmaceutical Technology,
L M College of Pharmacy,
Ahmedabad 380008, Gujarat,
India

Dr. Mahesh T. Chhabria

L M College of Pharmacy,
Ahmedabad, Gujarat, India

Deadline for manuscript
submissions:

31 December 2023

Message from the Guest Editors

Since the beginning of the pandemic, new “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” variants have emerged that can influence the airborne transmission, virulence, and immune evasion of affected individuals. The neutralizing antibodies produced as a result of vaccination or post-recovery of COVID-19 are not providing sufficient immune protection against emerging SARS-CoV-2 variants. SARS-CoV-2 variant-specific vaccines are required for better protection. A range of treatment options has become available, specifically for the aged, those with underlying health conditions, and the immunocompromised.

This Special Issue seeks all types of manuscripts (e.g., reviews, research articles, and short communications) on the impact of the aged population and immunocompromised patients on SARS-CoV-2 variants, vaccine efficacy, and treatment outcomes.

We cordially invite you to contribute to this Special Issue to advance our knowledge of SARS-CoV-2 and determine the means to overcome the pandemic.



mdpi.com/si/125244

Special Issue